BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · Wyświetl na SEC EDGAR ↗ zamknij Paź 5, 2026 10-K/10-Q Sie 5, 2026
$8,02
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$6,0052tyg. minimum
$11,2252tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$2.05B
P/E (TTM)
-5.4
EPS (TTM)
$-1.49
Przychody (TTM)
$941M
Twoje odznaki
Zakres 52 tyg.
$6–$11
Ocena Analityków
BUY
Cena Docelowa
$21
P/E
-5.4
ROE
87.8%
Marża Zysku Netto
-40.9%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
BCRX Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$8.02
Kapitalizacja Rynkowa (MRQ)
$2.05B
P/E (TTM)
-5.4
EPS (TTM)
$-1.49
Przychody (TTM)
$941M
ROE (TTM)
87.8%
D/E Dług/Kapitał (MRQ)
-0.9
Zakres 52 tyg.
$6–$11
BCRX Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O BioCryst Pharmaceuticals, Inc. - Common Stock Przegląd firmy z Wikipedii
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealthcare
branżaBiotechnology
pracownicy435
krajUS
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$875M2016-12-31 → 2025-12-31
EPS$1.212020-12-31 → 2025-12-31
Wolny przepływ pieniężny$345M2016-12-31 → 2025-12-31
Marża netto-40.9%2016-12-31 → 2025-12-31
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | BCRX | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | -5.4średnia z 5 lat ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 2.2średnia z 5 lat ≈6.7 | ≈6.7 | 22.5 | Niedowartościowany | |
| P/B (MRQ) | -4.5średnia z 5 lat ≈-10.2 | ≈-10.2 | · | · | |
| EV / EBITDA | 5.1średnia z 5 lat ≈-281.5 | ≈-281.5 | · | · | |
| Cena / FCF (TTM) | 5.5średnia z 5 lat ≈-13.6 | ≈-13.6 | · | · | |
| Cena / Przepływy pieniężne (TTM) | 5.4średnia z 5 lat ≈-13.9 | ≈-13.9 | · | · | |
| EV / Przychody (TTM) | 2.2średnia z 5 lat ≈6.3 | ≈6.3 | · | · | |
| EV / FCF (TTM) | 5.6średnia z 5 lat ≈-14.4 | ≈-14.4 | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | BCRX | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża Operacyjna (TTM) | -33.3%średnia z 5 lat ≈-32.2% | ≈-32.2% | -247.1% | Najwyższa półka | |
| EBITDA Margin (Marża EBITDA) | 39.1%średnia z 5 lat ≈-31.8% | ≈-31.8% | -247.1% | Najwyższa półka | |
| Marża przed opodatkowaniem (TTM) | -40.5%średnia z 5 lat ≈-52.6% | ≈-52.6% | -765.9% | Najwyższa półka | |
| Marża Zysku Netto (TTM) | -40.9%średnia z 5 lat ≈-53.3% | ≈-53.3% | -225.1% | Najwyższa półka | |
| ROA (TTM) | -75.8%średnia z 5 lat ≈-18.2% | ≈-18.2% | -39.4% | Najwyższa półka | |
| ROE (TTM) | 87.8%średnia z 5 lat ≈42.1% | ≈42.1% | -59.7% | Słaby | |
| ROIC | -282.4%średnia z 5 lat ≈-118.5% | ≈-118.5% | -63.3% | Słaby |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | BCRX | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | -0.9średnia z 5 lat ≈-0.7 | ≈-0.7 | 0.2 | Niski dług | |
| Wskaźnik bieżący (MRQ) | 2.3średnia z 5 lat ≈3.7 | ≈3.7 | 10.1 | Niska płynność | |
| Wskaźnik Szybkości (MRQ) | 2.2średnia z 5 lat ≈2.5 | ≈2.5 | 5.8 | Niska płynność | |
| Dług długoterminowy / Kapitał własny (MRQ) | -0.9średnia z 5 lat ≈-0.7 | ≈-0.7 | · | · |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | BCRX | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 94.1%średnia z 5 lat ≈201.4% | ≈201.4% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 47.8%średnia z 5 lat ≈85.0% | ≈85.0% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 117.9% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | BCRX | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 1.7średnia z 5 lat ≈0.8 | ≈0.8 | 0.0 | Najwyższa półka | |
| Inventory Turnover (Rotacja zapasów) | 2.8średnia z 5 lat ≈0.9 | ≈0.9 | 2.0 | Najwyższa półka | |
| Receivables Turnover (Rotacja należności) | 9.4średnia z 5 lat ≈7.4 | ≈7.4 | 4.9 | Najwyższa półka | |
| Revenue / Employee (Przychody / pracownika) | ≈$2.0M | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
23.2%
Następny raport
Lis 02, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 3, 2026 | $0.30 | $0.12 | 148.1% |
| 31 marca 2026 | $-0.09 | $0.05 | -281.8% | |
| 31 grudnia 2025 | $0.01 | $0.04 | -74.1% | |
| 30 września 2025 | $0.06 | $0.04 | 67.1% | |
| 30 czerwca 2025 | $0.04 | $0.01 | 179.7% | |
| 31 marca 2025 | $0.00 | $-0.07 | 100.0% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.56 | $-2.28 | $-2.21 | $-1.57 | $-0.58 | $-0.11 | $0.25 | $0.45 | · | $0.02 | $0.65 | $1.05 | |
| Revenue / Share | $4.00 | $2.18 | $1.72 | $1.46 | $0.88 | $0.11 | $0.42 | $0.20 | · | $0.36 | $0.66 | · | |
| Cash Flow / Share | $1.59 | $-0.25 | $-0.49 | $-0.87 | $-0.79 | $-0.82 | $-0.77 | $-0.90 | · | $-0.73 | $-0.18 | · | |
| Cash / Share | $0.42 | $0.50 | $0.54 | $1.62 | $2.74 | $1.54 | $0.74 | $0.24 | · | $0.30 | $0.39 | $0.76 | |
| EPS (TTM) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.61 | $-0.61 | $-0.61 | $-0.61 | $-0.60 | · |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | · | 210,176,000 | 209,519,000 | 208,882,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | · | 219,885,000 | 219,886,000 | 215,261,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.78 | $-2.18 | · | $-1.84 | $-2.01 | $-2.16 | · | $-2.26 | $-2.30 | $-2.31 | · | $-2.17 | $-2.05 | $-1.74 | · | $-1.30 | |
| Revenue / Share | $0.82 | $0.65 | · | $0.72 | $0.74 | $0.68 | · | $0.57 | $0.53 | $0.45 | · | $0.46 | $0.44 | $0.36 | · | $0.41 | |
| Cash Flow / Share | · | $-0.26 | · | · | · | $-0.13 | · | · | · | $-0.26 | · | · | · | $-0.25 | · | · | |
| Cash / Share | $0.61 | $0.68 | · | $0.40 | $0.42 | $0.50 | · | $0.47 | $0.38 | $0.41 | · | $0.80 | $0.77 | $0.82 | · | $1.32 | |
| EPS (TTM) | $-1.49 | $-1.77 | · | $-0.05 | $-0.18 | $-0.26 | · | $-0.61 | $-0.73 | $-1.07 | · | $-1.25 | $-1.29 | $-1.21 | · | $-1.05 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $941M | $886M | · | $600M | $558M | $503M | · | $413M | $382M | $355M | · | $318M | $307M | $290M | · | $238M | |
| Net Income TTM | $-385M | $-458M | · | $-9M | $-36M | $-53M | · | $-124M | $-146M | $-209M | · | $-236M | $-243M | $-226M | · | $-193M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -6.7 | -5.4 | · | -151.8 | -49.8 | -28.8 | · | -12.5 | -8.5 | -4.7 | · | -5.7 | -5.5 | -6.9 | · | -12.0 | |
| P/S | 2.7 | 2.7 | · | 2.7 | 3.4 | 3.1 | · | 3.8 | 3.3 | 2.9 | · | 4.2 | 4.4 | 5.4 | · | 9.9 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| EV / Revenue | 2.8 | 2.9 | · | 2.6 | 3.3 | 3.2 | · | 4.3 | 4.0 | 3.6 | · | 4.7 | 4.8 | 5.7 | · | 9.8 | |
| Earnings Yield | -14.9% | -18.6% | · | -0.66% | -2.0% | -3.5% | · | -8.0% | -11.8% | -21.1% | · | -17.7% | -18.3% | -14.5% | · | -8.3% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $875M | $451M | $331M | $271M | $157M |
| Marża Operacyjna % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| Zysk netto | $264M | $-89M | $-227M | $-247M | $-184M |
| Rozwodniony EPS | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| Wskaźnik bieżący | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| Wskaźnik Szybkości | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $345M | $-53M | $-97M | $-163M | $-145M |
Właściciele instytucjonalni (13F) 345 emitentów · $2.8B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
345
Wartość posiadanych akcji
$2.8B
Nowe pozycje
55
Zamknięte pozycje
34
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 55 (-22 vs poprzedni kw.) | 34 (-5 vs poprzedni kw.) | 137 (+20 vs poprzedni kw.) | 87 (+8 vs poprzedni kw.) | +4.1M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $238 930 360 | 23 893 036 | 8,46% | Akcje |
| VANGUARD GROUP INC | $173 732 325 | 22 273 375 | 6,15% | Akcje |
| RA CAPITAL MANAGEMENT, L.P. | $158 271 860 | 15 827 186 | 5,61% | Akcje |
| STATE STREET CORP | $151 910 980 | 15 191 098 | 5,38% | Akcje |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150 964 030 | 15 096 403 | 5,35% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $113 642 360 | 11 364 236 | 4,03% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111 391 580 | 11 139 158 | 3,95% | Akcje |
| TCG Crossover Management, LLC | $110 209 680 | 11 020 968 | 3,90% | Akcje |
| PERCEPTIVE ADVISORS LLC | $103 088 880 | 10 308 888 | 3,65% | Akcje |
| JANUS HENDERSON GROUP PLC | $84 853 520 | 8 908 506 | 3,01% | Akcje |
| Vestal Point Capital, LP | $83 000 000 | 8 300 000 | 2,94% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $67 753 490 | 6 775 349 | 2,40% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $62 493 232 | 6 248 046 | 2,21% | Akcje |
| Aberdeen Group plc | $53 108 710 | 5 310 871 | 1,88% | Akcje |
| UBS Group AG | $50 782 800 | 5 078 280 | 1,80% | Akcje |
| BANK OF AMERICA CORP /DE/ | $48 012 840 | 4 801 284 | 1,70% | Akcje |
| GOLDMAN SACHS GROUP INC | $44 818 738 | 4 481 874 | 1,59% | Akcje |
| Frazier Life Sciences Management, L.P. | $40 092 400 | 4 009 240 | 1,42% | Akcje |
| Nuveen, LLC | $40 072 370 | 4 007 237 | 1,42% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $33 947 290 | 3 394 729 | 1,20% | Akcje |
| TWO SIGMA ADVISERS, LP | $31 895 074 | 4 089 112 | 1,13% | Akcje |
| RP Management, LLC | $28 846 155 | 3 846 154 | 1,02% | Akcje |
| JANE STREET GROUP, LLC | $27 626 830 | 2 762 683 | 0,98% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $27 187 810 | 2 718 781 | 0,96% | Akcje |
| Fisher Asset Management, LLC | $26 040 270 | 2 604 027 | 0,92% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $25 302 900 | 2 530 290 | 0,90% | Akcje |
| Kynam Capital Management, LP | $25 226 600 | 2 522 660 | 0,89% | Akcje |
| Candriam S.C.A. | $25 125 293 | 2 514 949 | 0,89% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23 532 910 | 2 353 291 | 0,83% | Akcje |
| RICE HALL JAMES & ASSOCIATES, LLC | $23 320 430 | 2 332 043 | 0,83% | Akcje |
| NORTHERN TRUST CORP | $22 557 310 | 2 255 731 | 0,80% | Akcje |
| AQR CAPITAL MANAGEMENT LLC | $22 143 020 | 2 214 302 | 0,78% | Akcje |
| MORGAN STANLEY | $19 996 852 | 1 999 684 | 0,71% | Akcje |
| Nantahala Capital Management, LLC | $19 011 600 | 1 901 160 | 0,67% | Akcje |
| Eversept Partners, LP | $18 656 530 | 1 865 653 | 0,66% | Akcje |
| ORBIMED ADVISORS LLC | $18 520 000 | 1 852 000 | 0,66% | Akcje |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18 449 120 | 1 844 912 | 0,65% | Akcje |
| STIFEL FINANCIAL CORP | $18 262 340 | 1 826 234 | 0,65% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $17 595 730 | 1 759 573 | 0,62% | Akcje |
| CITADEL ADVISORS LLC | $17 591 600 | 1 759 160 | 0,62% | Akcje |
| JUPITER ASSET MANAGEMENT LTD | $16 428 740 | 1 642 874 | 0,58% | Akcje |
| IMC-Chicago, LLC | $16 343 360 | 1 634 336 | 0,58% | Akcje |
| Parkman Healthcare Partners LLC | $16 242 790 | 1 624 279 | 0,58% | Akcje |
| Legal & General Group Plc | $14 555 141 | 1 455 514 | 0,52% | Akcje |
| OP Asset Management Ltd | $13 409 900 | 1 340 990 | 0,48% | Akcje |
| Invesco Ltd. | $12 337 830 | 1 233 783 | 0,44% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11 956 510 | 1 195 651 | 0,42% | Akcje |
| Pictet Asset Management Holding SA | $11 951 392 | 1 249 771 | 0,42% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $11 740 520 | 1 174 052 | 0,42% | Akcje |
| FIRST TRUST ADVISORS LP | $11 204 690 | 1 120 469 | 0,40% | Akcje |
Aktywiści i właściciele 5%+ 15 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 zgłoszenia | 31 lipca 2018 | · | Pierwotne zgłoszenie | · | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2 kwietnia 2018 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 zgłoszenia | 16 sierpnia 2016 | · | Pierwotne zgłoszenie | · | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 zgłoszenia | 23 października 2012 | · | Pierwotne zgłoszenie | M&A / sprzedaż | SEC |
| Julian C. Baker, Felix J. Baker ×4 zgłoszenia | 13 października 2011 | · | Pierwotne zgłoszenie | · | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 zgłoszenia | 20 sierpnia 2007 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca | 7 grudnia 2005 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca | 7 grudnia 2005 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca | 7 grudnia 2005 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca | 13 października 2005 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca | 26 lutego 2004 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca | 25 lutego 2004 | · | Pierwotne zgłoszenie | · | SEC |
| Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca, Niezgłoszona osoba raportująca | 24 lutego 2004 | · | Pierwotne zgłoszenie | · | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 zgłoszenia | 31 października 2003 | · | Pierwotne zgłoszenie | · | SEC |
| William W. Featheringill | 14 lutego 2002 | · | Pierwotne zgłoszenie | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 51 insiderów · 21 dyrektorzy generalni · 30 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17 grudnia 2025 A | 268 700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19 grudnia 2024 A | 377 867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21 lutego 2020 A | 125 176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16 marca 2011 M | 57 102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22 grudnia 2025 M | 952 583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14 marca 2008 A | 65 730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13 maja 2026 M | 400 703 | 0 | 7 | $-3 461 969 |
| Sandeep Menon | Chief R&D Officer | 6 kwietnia 2026 A | 205 150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31 marca 2025 F | 377 318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19 grudnia 2022 A | 16 653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14 listopada 2022 M | 298 541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10 marca 2022 M | 37 954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15 grudnia 2020 A | 45 000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28 stycznia 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15 marca 2012 F | 24 124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 7 lutego 2011 A | 9 766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12 marca 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31 lipca 2008 P | 3 048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31 lipca 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31 lipca 2007 P | 3 659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16 maja 2007 A | 1 928 | 0 | 0 | $0 |
| Amy E Mckee | Dyrektor | 31 sierpnia 2026 A | 47 821 | 0 | 1 | $-100 285 |
| Jill C. Milne | Dyrektor | 31 sierpnia 2026 A | 33 226 | 0 | 0 | $0 |
| Steven Frank | Dyrektor | 31 sierpnia 2026 A | 36 747 | 0 | 0 | $0 |
| Jon P Stonehouse | Dyrektor | 31 sierpnia 2026 A | 1 340 419 | 0 | 0 | $0 |
| Vincent Milano | Dyrektor | 31 sierpnia 2026 A | 109 642 | 0 | 0 | $0 |
| Theresa Heggie | Dyrektor | 11 czerwca 2026 A | 80 646 | 0 | 1 | $-504 823 |
| Machelle Sanders | Dyrektor | 11 czerwca 2026 A | 45 936 | 0 | 1 | $-68 544 |
| Steven K Galson | Dyrektor | 11 czerwca 2026 A | 27 794 | 0 | 0 | $0 |
| Alan G Levin | Dyrektor | 11 czerwca 2026 A | 79 565 | 0 | 0 | $0 |
| Nancy J Hutson | Dyrektor | 12 czerwca 2025 A | 99 138 | 0 | 0 | $0 |
| George B Abercrombie | Dyrektor | 12 czerwca 2024 A | 36 431 | 0 | 0 | $0 |
| Steve Aselage | Dyrektor | 12 czerwca 2024 A | 70 159 | 0 | 0 | $0 |
| Kenneth B Lee JR | Dyrektor | 13 czerwca 2023 A | 68 863 | 0 | 0 | $0 |
| Robert Alexander Ingram | Dyrektor | 28 lutego 2023 A | 100 198 | 0 | 0 | $0 |
| Stanley C Erck | Dyrektor | 28 listopada 2018 M | 48 333 | 0 | 0 | $0 |
| Fred Cohen | Dyrektor | 20 czerwca 2018 A | 119 410 | 0 | 0 | $0 |
| Sanj K Patel | Dyrektor | 24 maja 2017 A | · | 0 | 0 | $0 |
| Charles A Sanders | Dyrektor | 29 lutego 2016 A | 12 971 | 0 | 0 | $0 |
| Peder Jensen | Dyrektor | 2 maja 2014 A | 60 000 | 0 | 0 | $0 |
| John L Higgins | Dyrektor | 23 maja 2012 A | · | 0 | 0 | $0 |
| HOROVITZ ZOLA P | Dyrektor | 23 maja 2012 A | 3 000 | 0 | 0 | $0 |
| Stephen R Biggar | Dyrektor | 12 maja 2011 A | · | 0 | 0 | $0 |
| Beth C Seidenberg | Dyrektor | 13 maja 2010 A | 3 000 | 0 | 0 | $0 |
| William W Featheringill | Dyrektor | 13 maja 2010 A | 231 538 | 0 | 0 | $0 |
| William M Spencer III | Dyrektor | 16 maja 2007 A | 186 761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | Dyrektor | 16 maja 2007 A | 451 900 | 0 | 0 | $0 |
| Charles E Bugg | Dyrektor | 18 marca 2007 A | 62 439 | 0 | 0 | $0 |
| GORDON CARL L | Dyrektor | 17 maja 2006 A | 1 100 000 | 0 | 0 | $0 |
| John A Montgomery | Dyrektor | 4 listopada 2003 M | 46 785 | 0 | 0 | $0 |
| Randolph C Steer | · | 21 maja 2008 A | · | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 41 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2,34% | 1 193 733 SH | 2 października 2026 | Dziennie |
| BBP · ETFis Series Trust I | 1,42% | 155 993 NS | 31 lipca 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 0,99% | 510 NS | 31 lipca 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,92% | 1 078 429 NS | 31 lipca 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0,62% | 248 560 NS | 31 lipca 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,59% | 324 702 NS | 31 lipca 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,36% | 516 595 NS | 31 lipca 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,22% | 73 039 SH | 2 października 2026 | Dziennie |
| PWS · Pacer Funds Trust | 0,17% | 4 436 NS | 31 lipca 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,14% | 249 665 SH | 19 sierpnia 2026 | Dziennie |
| ESSC · Strategy Shares | 0,14% | 5 593 NS | 31 lipca 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,14% | 18 119 SH | 2 października 2026 | Dziennie |
| IBB · iShares Trust | 0,13% | 1 651 139 SH | 11 września 2026 | Dziennie |
| IWO · iShares Trust | 0,13% | 2 178 966 SH | 11 września 2026 | Dziennie |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,11% | 174 467 NS | 31 lipca 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 64 429 NS | 31 lipca 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,07% | 46 799 NS | 31 lipca 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 1 339 774 SH | 19 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,07% | 111 471 NS | 31 lipca 2026 | N-PORT |
| ISCG · iShares Trust | 0,06% | 75 067 SH | 11 września 2026 | Dziennie |
| IWM · iShares Trust | 0,06% | 5 937 121 SH | 11 września 2026 | Dziennie |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,06% | 202 979 SH | 2 października 2026 | Dziennie |
| DFAS · Dimensional ETF Trust | 0,05% | 770 732 NS | 31 lipca 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,04% | 1 696 014 SH | 19 sierpnia 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2 837 341 SH | 19 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,03% | 624 412 SH | 19 sierpnia 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 99 007 NS | 31 lipca 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2 922 024 SH | 19 sierpnia 2026 | Dziennie |
| WSML · iShares Trust | 0,01% | 11 812 SH | 11 września 2026 | Dziennie |
| IWV · iShares Trust | 0,00% | 72 998 SH | 11 września 2026 | Dziennie |
| ITOT · iShares Trust | 0,00% | 336 323 SH | 11 września 2026 | Dziennie |
| DFUS · Dimensional ETF Trust | 0,00% | 52 194 NS | 31 lipca 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 36 571 NS | 31 lipca 2026 | N-PORT |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31 lipca 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 286 NS | 31 lipca 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 8 070 274 SH | 19 sierpnia 2026 | Dziennie |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 196 622 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 19 676 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,00% | 51 624 SH | 19 sierpnia 2026 | Dziennie |
| ISCB · iShares Trust | · | 10 494 SH | 11 września 2026 | Dziennie |
| SMLF · iShares Trust | · | 766 086 SH | 11 września 2026 | Dziennie |
BCRX Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 17 analityków
KUP
Średni cel
$17.00
+112,1%
5 29,4%
Mocne kupno
10 58,8%
Kup
2 11,8%
Trzymaj
0 0,0%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
11 analityków · 2026-10-05Średnia cel $20.73 +158,6%
← Poniżej wszystkich celów
Aktualna cena $8.02
Niski$11.00
Średnia$20.73
Wysoki$32.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| ADMA | $4.34B | 30.4 | 19.6% | 28.8% | 33.6% | 57.4% |
| VERA | · | -10.9 | · | · | -55.9% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
| ABSI | $529M | -4.2 | -38.2% | -4113.7% | -63.5% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
RBC Capital podnosi cenę docelową BioCryst Pharmaceuticals (BCRX) jako część przewidywania wyników Q1 2026 w biotechnologii
Yahoo Finance · 5 miesięcy temu
BioCryst (BCRX) zyskuje 7,10% na plotkach o przejęciu
Yahoo Finance · 6 miesięcy, 2 tygodnie temu
BioCryst Pharmaceuticals, Inc. (BCRX) Czy To Dobry Zakup Akcji Teraz?
Yahoo Finance · 6 miesięcy, 2 tygodnie temu
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 5, 2026